Maze Therapeutics reported positive phase 1 data for MZE-782, an oral inhibitor targeting SLC6A19 with potential applications in phenylketonuria (PKU) and chronic kidney disease (CKD). The company’s phase 1 results validated the drug’s antiproliferative activity and safety profile, encouraging transition to phase 2 trials scheduled for 2026. Alongside clinical progress, Maze raised $150 million in private financing to support development. These advances position Maze as a rising player in the rare disease and metabolic disorder space.